Clinical Trial VICCHEM1319


A Phase 3, Randomized, Open Label Trial of Lenalidomide/dexamethasone With or Without Elotuzumab in Subjects with Previously Untreated Multiple Myeloma

Principal Investigator(s)

Madan Jagasia


  • Protocol No. VICCHEM1319
  • Open Date: 08/07/2013
  • Staging: Phase III
  • Age Group: Adults
  • Scope: International
  • Objective: To compare the PFS of lenalidomide/dexamethasone + elotuzumab (LdE) versus lenalidomide/dexamethasone (Ld) in subjects with newly diagnosed, previously untreated multiple myeloma (MM).
  • Disease Sites: Multiple Myeloma
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: Dexamethasone; Elotuzumab; Lenalidomide
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01335399
  • Secondary Protocol No: CA204006



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.